QuidelOrtho Corporation $QDEL Shares Acquired by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC increased its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 222.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 833,791 shares of the company’s stock after buying an additional 574,877 shares during the quarter. QuidelOrtho comprises 1.3% of Rice Hall James & Associates LLC’s portfolio, making the stock its 23rd largest position. Rice Hall James & Associates LLC’s holdings in QuidelOrtho were worth $23,813,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Barclays PLC grew its stake in shares of QuidelOrtho by 4.7% in the fourth quarter. Barclays PLC now owns 111,027 shares of the company’s stock valued at $3,171,000 after buying an additional 4,949 shares in the last quarter. Stanley Capital Management LLC grew its stake in shares of QuidelOrtho by 6.6% in the fourth quarter. Stanley Capital Management LLC now owns 402,000 shares of the company’s stock valued at $11,481,000 after buying an additional 25,000 shares in the last quarter. First Trust Advisors LP grew its stake in shares of QuidelOrtho by 10.3% in the fourth quarter. First Trust Advisors LP now owns 29,005 shares of the company’s stock valued at $828,000 after buying an additional 2,715 shares in the last quarter. State Street Corp grew its stake in shares of QuidelOrtho by 1.3% in the fourth quarter. State Street Corp now owns 2,704,355 shares of the company’s stock valued at $77,236,000 after buying an additional 35,616 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of QuidelOrtho by 1.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 186,119 shares of the company’s stock valued at $5,316,000 after buying an additional 1,914 shares in the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on QDEL shares. Wall Street Zen lowered QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Sunday, April 12th. UBS Group restated a “neutral” rating and set a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 17th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Finally, Citigroup lowered their price objective on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $14.88.

QuidelOrtho Trading Up 3.1%

NASDAQ:QDEL opened at $14.57 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. The business’s 50 day moving average is $12.97 and its two-hundred day moving average is $21.15. QuidelOrtho Corporation has a 52 week low of $9.92 and a 52 week high of $35.58. The company has a market cap of $993.53 million, a PE ratio of -0.82 and a beta of 0.77.

QuidelOrtho (NASDAQ:QDEL) last released its earnings results on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The firm had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. During the same period in the prior year, the business earned $0.74 EPS. The company’s quarterly revenue was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, analysts predict that QuidelOrtho Corporation will post 1.83 EPS for the current year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.